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Background: A high incidence of adverse skin reactions following long-term oral administration of voriconazole in children with cystic ﬁbrosis
and allergic bronchopulmonary aspergillosis (ABPA). The aim was to study the pharmacokinetics of voriconazole in these patients and to deter-
mine a possible association between drug levels and adverse effects.
Methods: Multiple venous blood samples were collected for HPLC determination of voriconazole concentrations and routine blood tests. Adverse
events were recorded.
Results: No signiﬁcant correlation was found between incidence of photosensitivity and voriconazole serum levels in 6 of 8 children with ABPA.
80% of patients had trough voriconazole concentrationsb1000 ng/mL and were highly variable.
Conclusions: Long-term voriconazole therapy and greater sun exposure in Greece appear to play a major role in the occurrence of photosensitivity.
Steady-state plasma drug concentrations were found to be highly variable and below the recommended therapeutic range in most patients, without
any apparent negative inﬂuence on outcome.
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Aspergillus spp and Scedosporium apiospermun are the
most common filamentous fungi associated with clinical mani-
festations in patients with cystic fibrosis. Of these, Aspergillus
fumigatus is by far the most isolated from respiratory speci-
mens and can cause a wide range of diseases including allergic
bronchopulmonary aspergillosis (ABPA), aspergilloma in pre-
existing pulmonary cavities and invasive pulmonary aspergillo-
sis in immunocompromised patients. The most frequent mani-
festation of Aspergillus spp is ABPA with a prevalence of
approximately 1–15% in patients with cystic fibrosis [1].⁎ Corresponding author at: Faculty of Pharmacy, Department of Pharmaceutical
Technology, Laboratory of Biopharmaceutics and Pharmacokinetics, University
of Athens, Panepistimiopolis, Athens 157.71, Greece. Tel.: +30 210 7274676;
fax: +30 210 7274027.
E-mail address: kyroudi@pharm.uoa.gr (S.L. Markantonis).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.12.006The triazole antifungal drug, voriconazole (VRZ), has al-
most completely replaced amphotericin B for the treatment of
aspergillosis [2]. For the management of ABPA, oral glucocor-
ticoids remain primary therapy, but VRZ is now considered to
be a significant adjunct to therapy, in particular in patients with
serious complications from or refractory to corticosteroids. Only
2 prospective clinical trials have documented VRZ pharmocoki-
netics in children [3,4] and only 3 retrospective reviews have
dealt with therapeutic/toxic outcomes of VRZ therapy in children
specifically undergoing treatment for ABPA [5–7]. In the study
of Hilliard et al. [5], 13 pediatric CF patients with ABPA participat-
ed, 3 experienced adverse effects (2 photosensitivity skin reactions
and one hair loss), 3 a drop in IgE levels post treatment and steroid
dosing was not decreased. In contrast, Glackin et al. [6] reported
that only one out of 9 patients developed minor side effects (visual
disturbance and photosensitivity), but a mean decrease in IgE
levels post treatment as well as a decrease in steroid dosing.
Neely et al. [7] reported liver function test abnormalities notby Elsevier B.V. All rights reserved.
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dynamic association between VRZ trough concentrations
N1000 ng/ml and survival.
Visual disturbances (photophobia or blurred vision), liver
function test abnormalities and skin rashes/photosensitivity
are the most common adverse events ascribed to VRZ, and re-
lationships between VRZ mean or random concentrations and
these side effects have been found [8,9], with the exception of
adverse effects on the skin. Recently, several reports have asso-
ciated long-term voriconazole therapy with skin reactions such
as photosensitivity [10], the development of skin cancer [11,12]
and severe phototoxicity [13]. The incidence of photosensitivity
/ rashes has been reported to be 14% [5],16%[3] and 17.3%[14].
In the Cystic Fibrosis centre of the Children's Hospital, “Aghia
Sophia”, Athens, the incidence of photosensitivity in 8 ABPA pa-
tients treated with VRZ for a period of N6 months was particular-
ly high (75%) and prompted this study of the pharmacokinetics of
VRZ in cystic fibrosis patients, primarily to determine if VRZ
levels or other factors contributed to the occurrence of this side ef-
fect in these patients.
1.1. Aim of the study
In view of the observed high incidence of adverse skin reac-
tions following long-term oral administration of voriconazole
in children with cystic fibrosis and ABPA, our aim was to
study the pharmacokinetics of VRZ in patients with cystic fi-
brosis and fungal infections, in particular those with ABPA,
and to determine if drug levels achieved could possibly be asso-
ciated with the occurrence of these or other adverse effects.
2. Patients and methods
2.1. Study design
A prospective, open-labeled, uncontrolled observational
study. The study protocol was approved by the Scientific and
Ethics Committees of the “Aghia Sophia” Children's Hospital,
Athens. Written informed consent was obtained from parents/
carers of each child.
2.2. Patients and methods
In all, 10 CF patients, five male and five female, with medi-
an age 14.8 years (range: 10–19) entered the study. Diagnosis
of CF in all patients was based on typical clinical presentation
together with at least two positive sweat chloride tests and
two CF causing CFTR mutations. 8 of the patients had evidence
of ABPA according to current diagnostic criteria [15] that in-
cluded 5 or more of the following : a) acute or sub acute clinical
deterioration in lung function (FEV1) not attributable to anoth-
er etiology, b) total serum IgEN500 IU/ml, c) immediate
cutaneous reactivity to Aspergillus, d) presence of serum IgE
antibodies to A. fumigatus, e) precipitans/IgG antibodies to
A. fumigatus , f) new or recent pulmonary infiltrates, mucus
plugging or bronchiectasis that had not cleared with antibiotics
and standard physiotherapy. Of the remaining 2 patients one hadAspergillus Bronchitis and one Scedosporium apiospermum
exacerbation.
Patients were originally prescribed VRZ only if they did not
meet any of the following exclusion criteria: use of concomitant
medications known to be inhibitors, inducers or in any way in-
teract with voriconazole, a history of hypersensitivity to azoles,
liver disease defined as serum transaminase values more than
twice the upper normal limit or serum bilirubinN50 mmol/L.
Each patient received 100 or 200 mg voriconazole twice a
day depending on body weight. One blood sample was collect-
ed from each patient for genetic analysis. For voriconazole con-
centration measurements, venous blood was sampled, at steady
state, just before drug administration and at 1, 2 and 4 h there-
after. The samples for VRZ analysis were centrifuged immedi-
ately at 3500 rpm for 5 min at approximately 4 °C, and the
acquired plasma was stored at −70 °C until analysis.
At each trial visit, patients were asked whether they had ex-
perienced or were experiencing any adverse events with non-
leading questions.
At the screening visit and fortnightly thereafter, blood was
sampled for liver function tests and routine blood chemistry.
For most hematological and biochemical tests pathological
limits were set as defined by Lippert & Lehmen [16]. For en-
zymes the lower pathological limit was set at zero and the
upper limit at twice the upper limit of normal.2.3. Patient data collected and recorded
For each patient, the age, sex, weight, height, serum creati-
nine values, hepatic and renal function tests (aspartate amino-
transferase (AST), alanine amino transferase (ALT), alkaline
phosphatase (ALP), gamma-glutamyl transpeptidase (γGT)
and serum creatinine (SrCr)), voriconazole dose and duration
of administration, concomitant drug therapy were recorded.2.4. Quantitative analysis of plasma samples
Voriconazole plasma concentrations were determined using
a previously validated HPLC method [17]. The dynamic
range of the assay was 200 to 10,000 ng/ml. The lower limit
of quantification was 100 ng/ml. At 200 ng/ml the inter-day co-
efficient of variation (c.v.) was 7.46%, at 600 ng/ml, 4.3%, at
4000 ng/ml 1.85% and 10,000 ng/ml, 1.21%, while the intra-
day c.v. at 200 ng/ml was 0.6%, at 600 ng/ml, 0.58%, at
4000 ng/ml, 0.53% and 10,000 ng/ml , 0.51%. A total of
seven calibration standards were prepared per analytical run.2.5. DNA extraction and genotyping
DNA was extracted from peripheral blood leukocytes using
the Blood DNA kit (QiAgen, Germany) according to standard
protocols. Polymorphisms of CYP2C19*2 (rs4244285) and
CYP2C19*3 (rs4986893) were analysed using a real-time poly-
merase chain reaction (PCR) allelic discrimination assay with a
Lightcycler LC 480 Instrument (Roche diagnostics, Germany).
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Quantitative variables are expressed as mean±standard de-
viation (SD) for normally distributed variables, or as median
and range when distribution departed from normality. For
each patient, the age, weight, height, sampling time, adminis-
tered dose, hepatic and renal function test values, achieved con-
centrations of VRZ in serum and all pharmacokinetic
parameters were defined as quantitative continuous variables.
All reported P values are two-sided. Pearson correlation tests
were performed and a P value of b0.05 was considered statisti-
cally significant. Statistical processing and data analysis were
performed with GraphPad Prism 4 software (GraphPad Soft-
ware Inc.).2.7. Pharmacokinetic evaluations
Single dose and multiple dose paediatric studies have con-
cluded that voriconazole pharmacokinetics could be described
by a linear pharmacokinetic model [14]. Hence, pharmacoki-
netic parameters of VRZ in serum were estimated from
concentration-time data of individual patients by non-
compartmental, steady-state analysis using the WinNonLin
pharmacokinetic software package (Pharsight Co. Mountain
View, CA).Table 1
Patient characteristics, voriconazole and concomitant drugs administration.
Patient Sex Age
(years)
Weight
(kg)
Dose of
voriconazole
(mg)*1
Days of
therapy
prior to
sampling
1 F 15.4 54 200 112
2 F 16.7 54 200 395
3 F 16.8 41 200 411
4 F 13.4 34 100 20
5 F 12.5 28 100 338
6 M 19 60 200 373
7 M 10.3 36 100 360
8 M 15.2 41 200 322
9 M 14.8 40 200 448
10 M 11.6 58 200 210
*1 twice a day; shaded rows patients without Allergic bronchopulmonary Asperg3. Results
Patient characteristics, details of VRZ and concomitant drug
therapy are presented in Table 1. Adverse effects ascribed to
VRZ are shown in Table 2. Examples of study patients present-
ing photosensitivity during VRZ treatment (Fig. 1). Laboratory
values regarding liver and renal function tests during VRZ treat-
ment were within normal ranges, with the exception of the γGT
levels in 1 patient, AST, ALT and γGT levels in 2 patients
(Table 2). ALP levels were above normal (median 232 (range:
137–555)) in all but 1 patient (patient 6). Steady-state pharmaco-
kinetic parameters of VRZ are presented in Table 3 and individ-
ual concentration-time curves of VRZ in the children with
cystic fibrosis, with and without ABPA are shown in Fig. 2.
Determination of the CYP2C19 genotype of all study pa-
tients, except patient 3, yielded the following results : Pa-
tient 2 was found to be heterozygous for the genetic
variant CYP2C19*2 enzyme (G/A, rs4244285) and homozy-
gous wild type for the CYP2C19*3 (G/G, rs4986893) and
thus a poorer (intermediate) metabolizer of CYP2C19 sub-
strates; patient 9 was characterized as a homozygous poor
metabolizer at CYP2C19*2 and homozygous wild type for
the CYP2C19*3, while the remaining patients were found
to be homozygous wild type for both CYP2C19*2 and
CYP2C19*3 and thus would be expected to metabolize the
drug more extensively.Oral
steroids
Antimicrobial agents
administered during
voriconazole treatment
Other medications
N Amoxicillin and clavulanic
acid, gentamicin (inh) 
Pancreatic enzymes, Vits
A,D,E, acetylcysteine 
Y Colistin(inh) Pancreatic enzymes, Vits
A,D,E, salbutamol 
N Azithromycin,
tobramycin(inh),
colistin(inh) 
Pancreatic enzymes, Vits
A,D,E,K, alendronate,
bromhexine  
N Pancreatic enzymes, Vits
A,D,E,K, acetylcysteine 
N Minocycline, colistin(inh) Pancreatic enzymes, Vits
A,D,E,K, acetylcysteine,
dornase Alpha 
N Azithromycin,
gentamicin(inh)
Cotrimoxazole,
colistin(inh)
Pancreatic enzymes, Vits
A,D,E,K, montelukast 
Y Pancreatic enzymes, Vits
A,D,E, acetylcysteine,
salbutamol 
N Cotrimoxazole,
gentamicin(inh) 
Pancreatic enzymes, Vits
A,D,E,K, ursodiol,
acetylcysteine 
Y Tobramycin (inh) Pancreatic enzymes, Vits
A,D,E,K, alendronate,
ursodiol, bromhexine,
montelukast, salbutamol,
dornase Alpha 
Y Amoxicillin and clavulanic
acid, colistin (inh)
Pancreatic enzymes, Vits
A,D,E,K, acetylcysteine,
montelukast 
illosis (ABPA); inh :inhaled.
Table 2
Observed adverse effects from voriconazole therapy.
Patient Liver function tests Skin reactions Optical reactions CNS Others
1
2
3 Increase in GGT between days 72 and 123 Photosensitivity,
hair loss
4
5 Mild photosensitivity
6
7 Increase in AST, ALT, GGT-treated Photosensitivity
8 Photosensitivity, dermatitis Optical disturbances Headaches
9 High AST, ALT, GGT Photosensitivity, cheilitis photophobia Tremor
10 Photosensitivity
AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = gamma-glutamyl transpeptidase.
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4.1. Adverse effects
Six of the 8 children with ABPA (75%) experienced adverse
effects attributable to VRZ (Table 2). All six ABPA patients de-
veloped photosensitivity reactions, of these one patient also de-
veloped dermatitis, optical disturbances and headaches, one
cheilitis and tremor and one exhibited hair loss. Photosensitiv-
ity reactions were particularly troublesome for our paediatric
patients in particular in view of their consistent nature and the
need for long-term VRZ administration. No significant correla-
tion was found between the incidence of photosensitivity and
VRZ serum levels.
Various mechanisms for VRZ –induced photosensitivity have
been proposed. Based on the fact that CF patients commonly re-
ceive vitamin A supplementation, Denning and Griffiths [18]
first hypothesized that VRZ may inhibit a step in the breakdown
of all-trans-retinol resulting in the accumulation of its intermediate
metabolite, all-trans retinoic acid or tretinoin, known to cause var-
ious skin reactions sensitive to exposure to ultraviolet light. Cheng
et al. [19] also believed that this mechanism may have been re-
sponsible for the cutaneous manifestations they encountered inFig. 1. Photosensitivity/rash durfive of six CF patients receiving VRZ. Another theory produced
by Denning and Griffiths [18] was the possibility that VRZ or
one of the by-products of its metabolism could elicit a phototoxic
reaction. Subsequently, Cowen et al. [12], in a retrospective review
published in 2010 suggested that VRZ photosensitivity may not be
a result of the drug itself but its major metabolite, voriconazole
N-oxide, which has been found to absorb in the UVA and UVB
ranges and thus may act as a chromophore for phototoxicity.
Our study patients were all receiving vitamin A supplements,
but in view of the fact that: only six of the ten study patients de-
veloped photosensitivity; VRZ inhibition of hepatic cytochrome
p-450 enzymes has not been confirmed in vivo; routinely mea-
sured retinol levels were within normal limits; the retinol plasma
levels required to produce various skin rashes is unknown and
that a relationship between VRZ metabolism and phototoxicity
has not yet been confirmed, we cannot attribute the frequent
occurrence of photosensitivity in our patients to accumulation
of either retinoic acid or voriconazole N-oxide.
Photosensitivity skin reactions are however clearly associat-
ed with long-term VRZ therapy[10,14,18]. Our ABPA patients
all received VRZ for over 6 months. We believe that it is possi-
ble that the higher incidence of photosensitivity in our patients
was mainly due to greater exposure to sunlight bearing in minding voriconazole treatment.
Table 3
Steady-state pharmacokinetic parameters of voriconazole, estimated from the concentration-time data by non-compartmental analysis, following its oral administration
to pediatric patients with cystic fibrosis (N=10).
No. Dose
(mg/12h) h)
Cmin
ng/mL)
Cmax 
(ng/mL)
Cssave 
(ng/mL)
t½
(h)
AUC0-12h
(mg*h/L)
1 200 611 3204 610.5 4.4  17.6
2 200 690 3030 690.3 4.8 18.4
3 200 2313 3918 2312.5 15.0 36.7
4 100 207 633 207.2 7.3 5.1
5 100 244 708 243.6 7.2 5.0
6 200 382 1429 382.1 6.2 8.4
7 100 218 654 217.9 9.7 4.2
8 200 584 2523 584.3 4.8 17.5
9 200 1547 5673 3395.1 5.5 42.4
10 200 468 1852 468.4 5.7 10.9
Shaded rows: patients without ABPS; Cmax: maximum voriconazole plasma concentration; Cmin: drug concentration at 0 hours i.e. the 12 hour-sample of the pre-
vious dose; Cave=steady-state average concentration; AUC0–12 h : area under the curve from the time of dosing to the time of next dose curve, determined by trap-
ezoidal rule from the ﬁrst to the last data point (AUCall=AUC0–12); t1/2: elimination half-life was calculated as ln2 /λΖ, where λΖ was estimated by log linear
regression of the terminal portion of the plasma concentration-time curve (based on the last three data points);
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Greece. All patients were warned to avoid sunlight during treat-
ment, but considering the basic need for all children to partici-
pate in outdoor activities (particularly male patients), it may
arguably have been difficult for them to adhere to these
precautions.
Three patients had clinically significant elevations in hepatic
enzymes: AST, ALT and γ-GT levels (patients 7 and 9) and
γ-GT levels (patient3). Peak serum VRZ levels in patients 9
and 3 were the highest noted among those study patients who
were prescribed a 200 mg×2 daily VRZ dose (Table 3), while
in patient 7, VRZ levels were low following a 100 mg×2
dose (Table 3). After decreasing the dose of VRZ, patient 9 pre-
sented an improvement in hepatic function and when the full
dose of VRZ was restarted the side effect did not reappear.
The risk of AST, ALP but not ALT abnormalities was found0
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Fig. 2. Voriconazole steady-state concentrations in 10 pediatric study patients
with cystic fibrosis.to be statistically associated to VRZ plasma concentrations in
one study [8] and to increase by 7%–17% for every 1 μg/ml in-
crease in concentration in another [9]. This association was ap-
parent in patients 3 and 9, but not in patient 7. Among the liver
function tests, only γ-GT levels were found to statistically asso-
ciated with Cmax and Cmin VRZ serum levels (p=0.0374 and
b0.0001) in our study.
Visual disturbances were noted in only two patients (patients
8 and 9) despite the fact that these have been reported to be the
most common adverse effects of VRZ [3,8,20,21]. A significant
relationship between plasma VRZ concentration and the odds
of a visual adverse event has been revealed. The probability
of a visual adverse event has been found to increase from 18
to 31%, with a change in plasma concentration from 0 to
9 mg/L [8]. The Cpssave of VRZ in patient 9 was the highest
among the 10 study patients (3395.1 ng/L) and this supports
the existence of the above relationship, but in patient 8 the
Cpssave was not exceptionally high (584.3 ng/L) (Table 3).4.2. Voriconazole pharmacokinetics
VRZ maintenance doses, 100 and 200 mg twice daily (2.8 to
5.0 mg/kg), produced highly variable drug levels in plasma e.g.
Cmax and AUC values from 200 mg doses ranged between
1429 and 5673 ng/mL and 8.4 and 42.4 mg h/L, respectively.
(Fig. 2, Table 3). However, when VRZ doses were considered
based on mg/kg, significant correlations were found between
the doses received and achieved Cmax values (p=0.0037)
and estimated AUC values (p=0.0015). Cpave values were
also found to be significantly correlated with the mg/kg dose
(p=0.0083). Consequently, the different mg/kg doses adminis-
tered to the study patients contributed to the observed variabil-
ity in VRZ concentrations. Other factors that have been found
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patients, age and genetic polymorphism of the cytochrome
CYP2C19 [3,22] and in cystic fibrosis, abnormal disposition
of drugs leading to pharmacokinetic changes such as increased
volume of distribution, decreased plasma concentration and en-
hanced renal and non-renal elimination [23].
With increasing age the near-linear pharmacokinetics of VRZ,
described in children (2 to b12 years old) [3,14], becomes non-
linear and as our patients were aged between 10 and 19 years,
this could also have contributed to the variability observed. Fur-
thermore, as allelic polymorphisms of CYP2C19 have been
reported to strongly influence voriconazole exposure [24], the
CYP2C19 genotype of all the patients, except for patient 3, were
determined. Patient 2 was characterized as a poorer (intermediate)
metabolizer and patient 9 as a homozygous poor metabolizer of
CYP2C19 substrates, while the remaining patients were character-
ized as more extensive metabolizers. In line with these findings,
the highest AUC0–12 h and Cmax values for VRZ were found
for Patient 9, followed by patient 3 (for whom the genotype
could not be determined), and then by patient 2, suggesting that
VRZ exposure in the study patients may have been influenced
by genotype as well.
Estimated t1/2 values, ranged from 4.4 to 9.7 h (mean 6.4 h)
in 9 of the 10 patients, compared with a reported t1/2 of 6–9 h
[25]. In one patient (patient 3) our t1/2 estimation was longer
than the duration of sampling (see Table 3) and therefore
must be regarded only as a rough estimation.
Trough VRZ concentrations, in the present study, ranged be-
tween 207 and 2313 ng/mL (Table 3). In the study of Pascual et
al. [22] a trough VRZ concentration of 1 mg/L was found to be
associated with a 70% probability of a successful outcome and
in the study of Neely et al. [7] this trough level was found to be
pharmacodynamically associated with survival. Eight of our
study patients had trough VRZ concentrationsb1000 ng/mL
and were highly variable, probably as a result of variability in
absorption of VRZ [7] (Table 3). Delayed drug absorption in
cystic fibrosis patients is considered to be due to altered GI
physiology [23].
Higher mean VRZ concentrations tend to have better re-
sponses, with optimal outcomes observed with mean concentra-
tions of 3000–4000 ng/mL [14]. Only in one patient (patient 9)
were Cpave concentrations within this range. Despite what ap-
pear to be sub-therapeutic VRZ concentrations in the majority
of our study patients, the use of VRZ in our patients with CF
and ABPA led to serological improvement (total serum IgE,
specific IgE on RAST), a lower frequency and adequate control
of exacerbations and tapering of the steroid dose to the extent
that 60% of our patients were not on steroid therapy at the
time of this study [26] (Table 1). A possible partial explanation
for the apparent efficacy of sub-therapeutic VRZ serum levels,
may be the reported substantial penetration of VRZ into the
pulmonary epithelial lining fluid achieving levels much higher
than the minimum inhibitory concentrations of Aspergillus spe-
cies (~0.5 mg/L) at the pulmonary site [27]. However, the clin-
ical relevance of this finding has not been yet to be established.
We acknowledge that our study has some limitations. Our
observations with respect to efficacy and sub-therapeutic VRZserum levels suggest that recommended therapeutic trough
levels should be lower in this patient group. However, our
study was not powered to study this relationship and our data
insufficient to support this finding. A suitably designed future
study, which should include individual patient analysis of an
adequate number of participants, is required to identify the sub-
group of patients who might benefit from lower therapeutic
VRZ levels. Furthermore, the possible role of the major metab-
olite, voriconazole N-oxide, in triggering photosensitivity [12]
was not investigated in our study, as metabolite levels were
not measured. The contribution of this metabolite to photosen-
sitivity should be investigated in future. Finally, recent studies
[24,28] have shown that the CYP2C19*17 variant, associated
with ultra rapid VRZ metabolism, may be partly responsible
for variability in VRZ exposure and our study patients were
not tested for this variant. Further investigation is needed to
verify the involvement of the CYP2C19*17 variant in the
observed variation in VRZ pharmacokinetics.
5. Conclusions
Our preliminary data, from a small group of cystic fibro-
sis patients with ABPA, suggest that VRZ concentrations
are not associated with observed photosensitivity in these
patients. Long-term VRZ therapy appears to play a major
role in the occurrence of photosensitivity, as may, we be-
lieve, greater sun exposure during spring, summer, autumn
and even winter in Athens, Greece.
VRZ pharmacokinetics in children are highly variable,
and this was confirmed in our cystic fibrosis patients with
ABPA. The difference in mg/kg doses and CYP2C19 geno-
type appear to contribute to this variability. The long-term
administration (N6 months) of 100 or 200 mg twice daily
VRZ doses achieve steady-state concentrations below the
range for optimal outcome in some ABPA patients, without
any apparent negative influence on outcome. Further suit-
ably powered studies, to assess the relationship between
VRZ pharmacokinetics and outcomes in cystic fibrosis pa-
tients with ABPA are warranted.
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